Additionally, other CXCR4/CXCL12 inhibitors have shown synergy with ICIs in vitro and these combination regimens are now being assessed in clinical trials for PDAC and myelofibrosis (NCT04177810, NCT02826486, NCT03168139, and NCT04177810) [9, 10]. Here, CXCR4 is linked to myelofibrosis.